Osteosarcoma
HC Beird, SS Bielack, AM Flanagan, J Gill… - Nature reviews Disease …, 2022 - nature.com
Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …
Targeting p53 pathways: mechanisms, structures, and advances in therapy
H Wang, M Guo, H Wei, Y Chen - Signal transduction and targeted …, 2023 - nature.com
The TP53 tumor suppressor is the most frequently altered gene in human cancers, and has
been a major focus of oncology research. The p53 protein is a transcription factor that can …
been a major focus of oncology research. The p53 protein is a transcription factor that can …
Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas
The TP53 tumor suppressor gene is frequently mutated in human cancers. An analysis of
five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer …
five data platforms in 10,225 patient samples from 32 cancers reported by The Cancer …
Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus
Oncogene amplification on extrachromosomal DNA (ecDNA) drives the evolution of tumours
and their resistance to treatment, and is associated with poor outcomes for patients with …
and their resistance to treatment, and is associated with poor outcomes for patients with …
Integrated proteogenomic characterization across major histological types of pediatric brain cancer
We report a comprehensive proteogenomics analysis, including whole-genome sequencing,
RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 …
RNA sequencing, and proteomics and phosphoproteomics profiling, of 218 tumors across 7 …
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-
wide screens in human cells,–. Whereas some cell types are amenable to genome …
wide screens in human cells,–. Whereas some cell types are amenable to genome …
Gain-of-function mutant p53 in cancer progression and therapy
Abstract p53 is a key tumor suppressor, and loss of p53 function is frequently a prerequisite
for cancer development. The p53 gene is the most frequently mutated gene in human …
for cancer development. The p53 gene is the most frequently mutated gene in human …
Mutant p53 in cancer progression and targeted therapies
G Zhu, C Pan, JX Bei, B Li, C Liang, Y Xu, X Fu - Frontiers in oncology, 2020 - frontiersin.org
TP53 is the most frequently mutated tumor suppressor gene in human cancer. The majority
of mutations of p53 are missense mutations, leading to the expression of the full length p53 …
of mutations of p53 are missense mutations, leading to the expression of the full length p53 …
Signal pathways and precision therapy of small-cell lung cancer
M Yuan, Y Zhao, HT Arkenau, T Lao, L Chu… - Signal transduction and …, 2022 - nature.com
Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …
Metastasis as an evolutionary process
S Turajlic, C Swanton - Science, 2016 - science.org
Therapeutic advances in oncology have not fully translated to the treatment of metastatic
disease, which remains largely incurable. Metastatic subclones can emerge both early and …
disease, which remains largely incurable. Metastatic subclones can emerge both early and …